<H1>Chapter DOI: 10.1208/aapsj070103<br/>Cited-By Count: 81</H1><table border="1" width="30%"><tr><td>Total References</td><td>40</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>39</td></tr><tr><td>BibStructured Count</td><td width="10%">38</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>27</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>4</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>4</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>3</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Teo S, Resztak K, Scheffler M, et al. Thalidomide in the treatment of leprosy.<Emphasis Type="Italic">Microbes Infect</Emphasis>. 2002;4:1193&#8211;1202.</td><td><a href=http://dx.doi.org/10.1016/S1286-4579(02)01645-3>10.1016/S1286-4579(02)01645-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibBook</td><td>Stephens T, Brynner R.<Emphasis Type="Italic">Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine</Emphasis>. Cambridge, MA: Perseus Publishing; 2001.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.5860/choice.39-0973>10.5860/choice.39-0973</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Mellin G., Katzenstein M. The saga of thalidomide: neuropathy to embryopathy with case reports and congenital abnormalities.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1962;267:1184&#8211;1193.</td><td><a href=http://dx.doi.org/10.1056/NEJM196212062672305>10.1056/NEJM196212062672305</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Kelsey F. Thalidomide update: regulatory aspects.<Emphasis Type="Italic">Teratology</Emphasis>. 1988;38:221&#8211;226.</td><td><a href=http://dx.doi.org/10.1002/tera.1420380305>10.1002/tera.1420380305</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Newman L, Johnson E, Staples R. Assessment of the effectiveness of animal developmental toxicity testing for human safety.<Emphasis Type="Italic">Reprod Toxicol</Emphasis>. 1993;7:359&#8211;390.</td><td><a href=http://dx.doi.org/10.1016/0890-6238(93)90025-3>10.1016/0890-6238(93)90025-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Zeldis J, Williams B, Thomas S, Elsayed M. STEPS<Superscript>&#8482;</Superscript>: a comprehensive program for controlling and monitoring access to thalidomide.<Emphasis Type="Italic">Clin Ther</Emphasis>. 1999;21:319&#8211;330.</td><td><a href=http://dx.doi.org/10.1016/S0149-2918(00)88289-2>10.1016/S0149-2918(00)88289-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Raje N, Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy.<Emphasis Type="Italic">Curr Opin Oncol</Emphasis>. 2002;14:635&#8211;640.</td><td><a href=http://dx.doi.org/10.1097/00001622-200211000-00008>10.1097/00001622-200211000-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Singhal S, Mehta J, Desikan R, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1999;341:1565&#8211;1571.</td><td><a href=http://dx.doi.org/10.1056/NEJM199911183412102>10.1056/NEJM199911183412102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Drach J, Kaufman H, Woehrer S, Chott A, Zielinski C, Raderer M. Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.<Emphasis Type="Italic">Proc Am Soc Clin Oncol</Emphasis>. 2004;22: Abstract 6583.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Stirling D. Thalidomide and its impact on dermatology.<Emphasis Type="Italic">Semin Cutan Med Surg</Emphasis>. 1998;17:231&#8211;242.</td><td><a href=http://dx.doi.org/10.1016/S1085-5629(98)80019-9>10.1016/S1085-5629(98)80019-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Vasiliauskas E, Kam L, Abreu-Martin M, Papadakis K, Zeldis J, Targan S. An open-label step-wise dose escalating pilot study to evaluate the safety, tolerance and efficacy of low dose thalidomide in the treatment of chronically-active, steroid-dependent Crohns disease.<Emphasis Type="Italic">Gastroenterol</Emphasis>. 1999;116:A387. Abstract G3637.</td><td><a href=http://dx.doi.org/10.1016/S0016-5085(99)70136-8>10.1016/S0016-5085(99)70136-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Schey S, Cavenagh J, Johnson R, Child J, Oakervee H, Jones RA. UK myeloma forum phase III study of thalidomide: long-term follow-up and recommendations for treatment.<Emphasis Type="Italic">Leuk Res</Emphasis>. 2003;27:909&#8211;914.</td><td><a href=http://dx.doi.org/10.1016/S0145-2126(03)00027-4>10.1016/S0145-2126(03)00027-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Fine H, Wen P, Maher E, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade glioma.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2003;21:2299&#8211;2304.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.08.045>10.1200/JCO.2003.08.045</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Hwu W, Krown S, Menell J, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2003;21:3351&#8211;3356.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.02.061>10.1200/JCO.2003.02.061</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Maples W, Stevenson J, Sumrall S, Naughton M, Schwartz J. Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2004;22:4082.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity.<Emphasis Type="Italic">J Support Oncol</Emphasis>. 2003;1:194&#8211;205.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Corral L, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues.<Emphasis Type="Italic">Ann Rheum Dis</Emphasis>. 1999;58:(Suppl. 1),1107&#8211;1113.</td><td><a href=http://dx.doi.org/10.1136/ard.58.2008.i107>10.1136/ard.58.2008.i107</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, VolumeID, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Sampaio E, Sarno E, Gallily R, Cohn Z, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1991;173:699&#8211;703.</td><td><a href=http://dx.doi.org/10.1084/jem.173.3.699>10.1084/jem.173.3.699</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis>, 1999;9:1625&#8211;1630.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(99)00250-4>10.1016/S0960-894X(99)00250-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Munshi N. Recent advances in the management of multiple myeloma.<Emphasis Type="Italic">Semin Hematol</Emphasis>. 2004;41:21&#8211;26.</td><td><a href=http://dx.doi.org/10.1053/j.seminhematol.2004.03.002>10.1053/j.seminhematol.2004.03.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Richardson P, Schlossman R, Anderson K. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.<Emphasis Type="Italic">Blood</Emphasis>. 2002;100:3063&#8211;3067.</td><td><a href=http://dx.doi.org/10.1182/blood-2002-03-0996>10.1182/blood-2002-03-0996</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mufti</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>List</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gore</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ho</span> <span style='background:#DDDDDD'>A.</span></span></aug> Myelodysplastic syndrome. <i>Hematology (Am Soc Hematol Educ Program)</i>. <span style='background:#66FF66'>2003</span>;:<span style='background:#D279FF'>176&#8211;199</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>List</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kurtin</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Glinsmann-Gibson</span> <span style='background:#DDDDDD'>B</span></span>, et al.</aug> <span style='background:#CCCCFF'>Efficacy and safety of CC-5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS)</span>. <span style='background:#CCFF99'><i>Blood</i></span>. 2003; 102: Abstract 641.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Sison B, Bond T, Amato R, Crawford D, Crighton F. Phase II of CC-4047 in patients with metastatic hormone-refractory prostate cancer.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2004;22:4701.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Corral L, Muller G, Moreira A, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.<Emphasis Type="Italic">Mol Med</Emphasis>. 1996;2:506&#8211;515.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Moreira A, Sampaio E, Zmuidzinas A, Frindt P, Smith K, Kaplan G. Thalidomide exerts its inhibitory action on TNF-alpha by enhancing mRNA degradation.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1993;177:1675&#8211;1680.</td><td><a href=http://dx.doi.org/10.1084/jem.177.6.1675>10.1084/jem.177.6.1675</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Corral L, Haslett P, Muller G, et al. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-&#945;.<Emphasis Type="Italic">J Immunol</Emphasis>. 1999;163:380&#8211;386.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Haslett P, Corral L, Albert A, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.<Emphasis Type="Italic">J Exp Med</Emphasis>. 1998;187:1885&#8211;1982.</td><td><a href=http://dx.doi.org/10.1084/jem.187.11.1885>10.1084/jem.187.11.1885</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Bartlett J, Dredge K, Dalgleish A. The evolution of thalidomide and its IMiD<Superscript>&#174;</Superscript> derivatives as anti-cancer agents.<Emphasis Type="Italic">Nat Rev Cancer</Emphasis>. 2004;4:314&#8211;322.</td><td><a href=http://dx.doi.org/10.1038/nrc1323>10.1038/nrc1323</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.<Emphasis Type="Italic">Immunopharmacology</Emphasis>. 1996;31:213&#8211;221.</td><td><a href=http://dx.doi.org/10.1016/0162-3109(95)00050-X>10.1016/0162-3109(95)00050-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Verbon A., Juffermans N, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans.<Emphasis Type="Italic">Antimicrob Agents Chemother</Emphasis>. 2000;44:2286&#8211;2290.</td><td><a href=http://dx.doi.org/10.1128/AAC.44.9.2286-2290.2000>10.1128/AAC.44.9.2286-2290.2000</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Dredge K, Marriott J, Todryk S, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.<Emphasis Type="Italic">J Immunol</Emphasis>. 2002;168:3914&#8211;3919.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.168.10.4914>10.4049/jimmunol.168.10.4914</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Oliver S. The Th1/Th2 paradigm in the pathogenesis of scleroderma and its modulation by thalidomide.<Emphasis Type="Italic">Curr Rheumatol Rep</Emphasis>. 2000;2:486&#8211;491.</td><td><a href=http://dx.doi.org/10.1007/s11926-000-0025-7>10.1007/s11926-000-0025-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;305:1222&#8211;1232.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.048496>10.1124/jpet.102.048496</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Davies F, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.<Emphasis Type="Italic">Blood</Emphasis>. 2001; 98:210&#8211;216.</td><td><a href=http://dx.doi.org/10.1182/blood.V98.1.210>10.1182/blood.V98.1.210</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1994;91:4082&#8211;4085.</td><td><a href=http://dx.doi.org/10.1073/pnas.91.9.4082>10.1073/pnas.91.9.4082</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Dredge K, Marriott J, Macdonald C, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.<Emphasis Type="Italic">Br J Cancer</Emphasis>. 2002; 87:1166&#8211;1172.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6600607>10.1038/sj.bjc.6600607</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.<Emphasis Type="Italic">Leukemia</Emphasis>. 2001;15:1950&#8211;1961.</td><td><a href=http://dx.doi.org/10.1038/sj.leu.2402295>10.1038/sj.leu.2402295</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy.<Emphasis Type="Italic">Blood</Emphasis>. 2000;96:2943&#8211;2950.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Mitsiades N, Mitsiades C, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.<Emphasis Type="Italic">Blood</Emphasis>. 2002;99:4525&#8211;4530.</td><td><a href=http://dx.doi.org/10.1182/blood.V99.12.4525>10.1182/blood.V99.12.4525</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>